ANGELHOLM, Sweden, April 5 /PRNewswire/ -- March 9th this year, HemoCue won an important victory in a lawsuit against EKF-diagnostics GmbH in the District Court of Dusseldorf, Germany. Yesterday EKF was informed of HemoCue’s decision to enforce the District Court’s decision. This means that EKF no longer can manufacture, or sell, the infringing product.
Says HemoCue’s Director of Corporate Affairs, Clas Runnberg; “In our opinion, the decision, and the reasoning upon which it is based, is entirely in HemoCue’s favor. This made it very easy for us to determine that we wanted the first instance decision enforced immediately. We have also decided to exercise our right to request that EKF communicates information about sales of product covered by our patent.”
The decision is related to a patent involved in multiple processes, both in Germany and in the United States. Most likely, these will continue for years to come, but the company stills regards the victory as decisive. The Court in Dusseldorf is one of Europe’s most respected in patent litigation. Subject to appeal, the enforcement of the decision means that it is no longer permissible for EKF to manufacture the infringing product, nor is the company allowed to sell it in or out from Germany, irrespective of intended destination.
For additional product information, please visit
HemoCue is a leading global company in a field of diagnostic testing known as point-of-care testing. In 1982, the company introduced the first system making accurate hemoglobin testing possible outside the hospital environment. The system consists of an instrument and a disposable microcuvette used with each test. Since then, HemoCue has installed more than 200,000 systems world wide which are being used to deliver about 100 million tests each year.
HemoCue AB
CONTACT: Clas Runnberg, Director of Corporate Affairs, HemoCue AB, +46 43145 82 70, clas.runnberg@hemocue.se
Web site: http://www.hemocue.com//
